Yahoo Italia Ricerca nel Web

Risultati di ricerca

  1. 1 giorno fa · Venerdì Deutsche Bank ha mantenuto un outlook positivo su Tenet Healthcare (NYSE:THC), alzando l'obiettivo di prezzo del titolo a 126 dollari da 100 dollari e mantenendo il rating Buy. L'azienda ha sottolineato il forte potenziale di crescita dei ricavi e dell'EBITDA della società in seguito alle ...

  2. 2 giorni fa · Tenet’s lead asset, TNT119, also known as budoprutug, is an anti-CD19 targeted monoclonal antibody designed to deplete B-cells. TNT119 has a clinically validated mechanism of action, and is being advanced in indications with high unmet needs, including systemic lupus erythematosus (“SLE”), immune thrombocytopenia (“ITP”), and membranous nephropathy (“MN”).

  3. 13 ore fa · Eliem Therapeutics, Inc.and Tenet Medicines, Inc. a development-stage private biotechnology company, announced that the companies have entered into a definitive acquisition agreement whereby Eliem has agreed to acquire Tenet. The combined company plans to focus on advancing TNT 119, a potentially best-in class anti-CD19 antibody, designed for a ...

  4. 1 giorno fa · Eliem Therapeutics Inc (NASDAQ:ELYM) has agreed to acquire Tenet Medicines Inc., a development-stage private biotechnology company. The combined company plans to focus on advancing TNT119, an anti ...

  5. 4 giorni fa · Armed with only one word, Tenet, and fighting for the survival of the entire world, a Protagonist journeys through a twilight world of international espionage on a mission that will unfold in ...

    • Movie And TV Features Writer
  6. 2 giorni fa · Eliem shifts focus to autoimmunity with Tenet Medicines buyout. Following decisions in 2023 to back away from its lead neurological therapies and conserve cash, Eliem Therapeutics Inc. found a vote of investor confidence and a new direction through its acquisition of privately held Tenet Medicines Inc. and its anti-CD19 antibody for autoimmune ...

  7. 2 giorni fa · Eliem Therapeutics (NASDAQ:ELYM) on Thursday said, it would acquire Tenet Medicines, as the combined company plans to focus on clinical development of lead product candidate, TNT119, in upcoming ...

  1. Le persone cercano anche